In this @BioMedCentral article, the UCLA #Drug Discovery Lab performed in vivo studies to determine if DDL-112 can reduce brain EV/exosome production and proteopathic alpha synuclein (αSyn) spread in a #Parkinsons mouse model. https://t.co/4sK9tfyOWj
New research from Zhu et al. showed that "Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model"; published in @molecularbrain https://t.co/2SjCcNocvx #PD #alphasynuclein #exosome #EV #
New research from Zhu et al. showed that "Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model"; published in @molecularbrain https://t.co/a5UgR7fn0z #PD #alphasynuclein #exosome #EV #
New research from Zhu et al. showed that "Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model"; published in @molecularbrain https://t.co/fpLFSloq3y #PD #exosome #alphasynuclein #EV #